GENFIT appoints Dr. Pejvack Motlagh as chief medical officer

GENFIT (Euronext: GNFT) announced the appointment of Dr. Pejvack Motlagh as chief medical officer, effective immediately. The biopharmaceutical company, which focuses on rare and life-threatening liver diseases, made the announcement from its headquarters in Lille, France.

Dr. Motlagh will join the executive committee and oversee clinical development strategy, direction and execution. He will lead the clinical operations and strategy, biometrics and pharmacovigilance teams.

The new chief medical officer brings over 20 years of pharmaceutical and biotechnology industry experience. Most recently, he served as chief medical officer at Egle Therapeutics, which develops therapies targeting regulatory T cells for oncology and autoimmune diseases. He also held the chief medical officer role at Mablink Biosciences, a company specializing in antibody-drug conjugates.

"I am thrilled to join GENFIT at a pivotal moment, as Acute on-Chronic Liver Failure becomes an increasingly important focus among the liver disease community," Dr. Motlagh stated in the company's announcement.

GENFIT CEO Pascal Prigent said the appointment brings valuable expertise as the company advances its pipeline. "His deep expertise in clinical development and proven leadership in both large pharmaceutical and innovative biotech companies will be invaluable," Prigent stated.

GENFIT received accelerated approval for Iqirvo (elafibranor) from the FDA, European Medicines Agency and UK's Medicines and Healthcare products Regulatory Agency in 2024 for treating Primary Biliary Cholangitis. The drug is marketed by Ipsen in multiple countries.

The company currently focuses on Acute on-chronic Liver Failure and related conditions, while also targeting cholangiocarcinoma, urea cycle disorders and organic acidemia through its research and development portfolio.

You May Also Be Interested In

• FDA grants fast track status to Verastem's lung cancer drug VS-7375
• FG Merger II sets stockholder vote on BOXABL merger for June 9
• Fairfax prices $750 million senior notes offering at 6.200% interest